Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04958265Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of crovalimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Roche. Started Nov 2021; status: active, not recruiting.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT04958265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958265.